CrystalGenomics Invites Co (XKRX:083790) Total Liabilities : ₩99,046.2 Mil (As of Mar. 2024)

View and export this data going back to 2006. Start your Free Trial

What is CrystalGenomics Invites Co Total Liabilities?

CrystalGenomics Invites Co's Total Liabilities for the quarter that ended in Mar. 2024 was ₩99,046.2 Mil.

CrystalGenomics Invites Co's quarterly Total Liabilities declined from Sep. 2023 (₩158,609.50 Mil) to Dec. 2023 (₩97,822.55 Mil) but then increased from Dec. 2023 (₩97,822.55 Mil) to Mar. 2024 (₩99,046.20 Mil).

CrystalGenomics Invites Co's annual Total Liabilities increased from Dec. 2021 (₩118,300.63 Mil) to Dec. 2022 (₩129,190.04 Mil) but then declined from Dec. 2022 (₩129,190.04 Mil) to Dec. 2023 (₩97,822.55 Mil).

CrystalGenomics Invites Co Total Liabilities Historical Data

The historical data trend for CrystalGenomics Invites Co's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

CrystalGenomics Invites Co Total Liabilities Chart

CrystalGenomics Invites Co Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Total Liabilities

Get a 7-Day Free Trial

153,972.52

96,545.02

118,300.63

129,190.04

97,822.55

CrystalGenomics Invites Co Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Total Liabilities	Get a 7-Day Free Trial															149,348.49	217,446.26	158,609.50	97,822.55	99,046.20

CrystalGenomics Invites Co Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

CrystalGenomics Invites Co's Total Liabilities for the fiscal year that ended in Dec. 2023 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	55547.659	+	(29889.276	+	12083.128
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	0	+	302.485)
	=	97,822.5

Total Liabilities	=	Total Assets (A: Dec. 2023 )	-	Total Equity (A: Dec. 2023 )
	=	243115.542	-	145292.993
	=	97,822.5

CrystalGenomics Invites Co's Total Liabilities for the quarter that ended in Mar. 2024 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	57507.535	+	(28921.755	+	12253.75
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	0	+	363.163)
	=	99,046.2

Total Liabilities	=	Total Assets (Q: Mar. 2024 )	-	Total Equity (Q: Mar. 2024 )
	=	236309.116	-	137262.912
	=	99,046.2

CrystalGenomics Invites Co Total Liabilities Related Terms

Thank you for viewing the detailed overview of CrystalGenomics Invites Co's Total Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

CrystalGenomics Invites Co (XKRX:083790) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » CrystalGenomics Invites Co Ltd (XKRX:083790) » Definitions » Total Liabilities

Comparable Companies

Traded in Other Exchanges

N/A

Address

5F, A-dong, Korea Bio Park, 694-1, Sampyeong-dong, Bundang-gu, Seongnam-si, Gyeonggi, KOR, 463-400

Website

http://www.crystalgenomics.com

CrystalGenomics Invites Co Ltd Formerly CrystalGenomics Inc is one of the leading biopharmaceutical company in Korea. The company is mainly engaged in the research and development and new drug development. It develops innovative new drug development projects such as eradication antibiotics and molecular targeted anticancer drugs. It focuses on arthritic medicines and antibiotics which kill resistant bacteria. It also offers medicines for cancer, obesity, asthma, and diabetes.

CrystalGenomics Invites Co (XKRX:083790) Headlines

No Headlines